Forty Leading Organizations, Including 11 of the 20 Largest Dairy Companies in the World, Among First to Support New Global “Pathways to Dairy Net Zero” Climate Initiative
22.9.2021 10:00:00 EEST | Business Wire | Press release
Pathways to Dairy Net Zero, a ground-breaking new climate initiative, is launching today during Climate Week and just prior to the United Nations (UN) Food Systems Summit. Forty leading organizations, including 11 of the 20 largest dairy companies in the world, have already declared their support for the effort. Collectively, these supporters represent approximately 30 percent of total milk production worldwide.
The new climate initiative demonstrates the global dairy sector’s commitment to reducing GHG emissions while continuing to produce nutritious foods for six billion people and provide for the livelihoods of one billion people.
“Pathways to Dairy Net Zero will accelerate climate efforts already underway and drive further necessary action to reduce dairy’s emissions over the next decades. The dairy sector has a lot to offer to lead this transition,” said Hein Schumacher, Chief Executive Officer of Royal FrieslandCampina and Chairman of Global Dairy Platform.
“Mengniu is proud to join the global dairy sector in uniting behind this effort, the first of its kind in agriculture, because we must all do our part to meet this worldwide climate challenge,” said Minfang (Jeffrey) Lu, Chief Executive Officer and Executive Director of China Mengniu Dairy Company.
The initiative is underpinned by six key principles:
- Mitigation. Continuing to improve production and process efficiency to further reduce the GHG emissions intensity of milk and dairy products.
- Greenhouse gas removals. Enhancing production practices that protect carbon sinks (soil, forests, grass, peatlands) and complement natural ecosystems.
- Avoidance and adaptation. Improving practices such as feed, manure, fertilizer and energy management.
- Insets and offsets. Identify and implement alternative, credible reduction options.
- Measurement and monitoring. Measuring greenhouse gas emissions to plan mitigation and monitor progress.
- Overall support. Promoting the global initiative and emphasizing the dairy sector’s climate ambition.
Identifying and Clarifying Plausible Mitigation Options
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop science-based methodologies, tools and pathways that work for every dairy system.
Research is underway to identify where positive climate change action is possible. The study is led by Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre, research institutions from two of the Global Research Alliance on Agricultural Greenhouse Gases’ 65 member countries, backed up by data and analysis from the UN Food and Agriculture Organization.
Initial research found that the dairy sector already has the means to reduce a significant proportion of emissions - up to 40 percent in some systems - by improving productivity and resource use efficiency.1
Researchers are identifying plausible GHG mitigation pathways for different dairy systems globally, in particular methane reduction. The latest Intergovernmental Panel on Climate Change (IPCC) report2 reaffirmed that the main GHG challenge is the reduction of carbon dioxide, which remains in the atmosphere for centuries. The report also identified reductions in methane, a potent but short-lived climate pollutant that lasts only about 12 years in the atmosphere, as an immediate opportunity to address global warming.
Organizations Already Supporting Pathways to Dairy Net Zero
The list so far includes: Nestle, Dairy Farmers of America, Danone, Fonterra Co-operative Group, Royal FrieslandCampina, Arla Foods, China Mengniu Dairy Company, Saputo, Meiji Holdings, Savencia Fromage & Dairy, Agropur Dairy Cooperative, Ace Farming Company, Agri Networking Tools, Australian Dairy Products Federation, Brazzale, Dairy Australia, Dairy Connect, Dairy Farmers of Canada, Dairy Management Inc., Dairy UK, Dutch Dairy Association, First Milk, FOSS Analytics, Glanbia, Granja Tepeyac, Innovation Center for U.S. Dairy, International Dairy Foods Association, La Vida Lactea, Land O’Lakes, Lekhanath Dairy International, Leprino Foods Company, Livestock Improvement Corporation, Megmilk Snow Brand, Morinaga Milk Industry, National Dairy Development Board (India), National Milk Producers Federation (U.S.), Palmhouse Dairies, Pioneer Natural Capital, Royal DSM, U.S. Dairy Export Council.
For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.
About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.
Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.
The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
References
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- IPCC, 2021: Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change [Masson-Delmotte, V., P. Zhai, A. Pirani, S. L. Connors, C. Péan, S. Berger, N. Caud, Y. Chen, L. Goldfarb, M. I. Gomis, M. Huang, K. Leitzell, E. Lonnoy, J. B. R. Matthews, T. K. Maycock, T. Waterfield, O. Yelekçi, R. Yu and B. Zhou (eds.)]. Cambridge University Press. In Press.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005358/en/
Contact information
Kevin Burkum, Director of Communications
+1 847-627-3387
Kevin.Burkum@GlobalDairyPlatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
